Halozyme Therapeutics Inc (HALO) — Capital Reinvestment Ratio
Halozyme Therapeutics Inc (HALO) has a Capital Reinvestment Ratio of 0.02x as of September 2025, meaning it reinvests 0% of its operating cash flow ($178.60 Million) in capital expenditures ($3.03 Million). See HALO equity to assets ratio to measure how much of total assets are equity-financed.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Halozyme Therapeutics Inc Capital Reinvestment Ratio (2006–2024)
This chart tracks Halozyme Therapeutics Inc's Capital Reinvestment Ratio across 7 annual periods. Check Halozyme Therapeutics Inc cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Annual Capital Reinvestment Ratio for Halozyme Therapeutics Inc (2006–2024)
Year-by-year Capital Reinvestment Ratio for Halozyme Therapeutics Inc from 2006 to 2024. For live market cap and broader valuation context, see Halozyme Therapeutics Inc market capitalisation.
| Year | Reinvestment Ratio | Operating CF (USD) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2024 | 0.02x | $479.06 Million | $10.70 Million | ▼ -43.3% |
| 2023 | 0.04x | $388.57 Million | $15.29 Million | ▲ +96.5% |
| 2022 | 0.02x | $240.11 Million | $4.81 Million | ▲ +311.7% |
| 2021 | 0.00x | $299.44 Million | $1.46 Million | ▼ -89.2% |
| 2020 | 0.05x | $55.45 Million | $2.50 Million | ▲ +348.4% |
| 2017 | 0.01x | $134.05 Million | $1.35 Million | ▼ -80.5% |
| 2006 | 0.05x | $7.08 Million | $364.80K | — |